Generic Medicine Info
Indications and Dosage
Lower respiratory tract infections, Urinary tract infections
Adult: 1-2 g every 12 or 24 hr via IM or IV infusion. Up to 4 g/day may be used in severe infections.

Adult: 0.25-0.5 g as a single dose given by IM or IV infusion.
Renal Impairment
Lower respiratory tract infections,Urinary tract infections: In patients undergoing dialysis: 0.5-1 g daily is given after dialysis.
<100.5-1 g daily.
10-301-2 g daily.
Gonorrhoea: Dose adjustment may be needed.
Hypersensitivity to cephalosporins.
Special Precautions
Hypersensitivity to penicillins; renal impairment; porphyria. Monitor renal and haematologic status. Pregnancy, lactation.
Adverse Reactions
Nausea; vomiting; diarrhoea; hypersensitivity reactions; nephrotoxicity; convulsions; CNS toxicity; pseudomembranous colitis; hepatic dysfunction; haematologic disorders; pain at inj site (IM); thrombophloebitis (IV infusion); superinfection with prolonged use.
Drug Interactions
Renal clearance reduced by probenecid.
Lab Interference
Positive direct antiglobulin Coombs' test; falsely high values with Jaffe method of measuring creatinine concentrations; positive reactions for false glucose using copper-reduction reactions; transient increases in liver enzyme values.
Description: Cefodizime has uses similar to cefotaxime, but without active metabolite. It has variable activity against Citrobacter spp., and P. aeruginosa and B. fragilis are generally resistant.
Distribution: About 80% bound to plasma proteins. Widely distributed into body tissues and fluids. Crosses the placenta and detected in breast milk.
Excretion: Terminal elimination half-life of about 4 hr. Mainly excreted unchanged in the urine.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Cefodizime from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in